secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045997
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance
---------------------------------------------------------------------

- Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).
- Gross margin 72% (+480bps YoY); net loss narrowed to $0.9M ($0.02/share) from $3.7M.
- Adjusted EBITDA $10.0M (+84%, margin 17%); raised FY24 guidance: gross margin 72%, adj. EBITDA margin 22%.
- FDA approved MACI Arthro for knee cartilage repair; NexoBrid pediatric indication also approved.
- Cash $151M, no debt; operating cash flow $10.2M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/0001628280-24-045997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/vcel-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer